Approval · Notice of Compliance 10043 · 2009
VYVANSE: Notice of Compliance 10043
Issued February 19, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10043
- Date
- February 19, 2009
- Company
- Shire Canada IncLaval, QC, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Central nervous system stimulant for attention deficit hyperactivity disorder
Products in this notice
Medicinal ingredients
- LISDEXAMFETAMINE DIMESYLATE 30 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 50 MG per CAP